• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在管理和维持消灭脊髓灰质炎工作中开展合作的理由:储备需求与口服脊髓灰质炎疫苗的协调停用

The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.

作者信息

Thompson Kimberly M, Duintjer Tebbens Radboud J

机构信息

Kids Risk Project, Harvard School of Public Health, Boston, Massachusetts, USA.

出版信息

Medscape J Med. 2008;10(8):190. Epub 2008 Aug 13.

PMID:18924642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2562150/
Abstract

CONTEXT

Achieving successful eradication of a disease requires global cooperation to obtain a shared goal. Coordination of the endgame may seem an obvious requirement for success, but that does not ensure that cooperation will occur.

OBJECTIVE

To analytically explore the need for cooperation to maintain global polio eradication specifically related to creation of a global polio vaccine stockpile and coordination of oral poliovirus vaccine (OPV) cessation.

DESIGN

Using risk and decision analysis and game theoretical concepts, we modeled the importance of global cooperation in managing the risks associated with polioviruses for a time horizon of 20 years after successful global disruption of circulation of wild polioviruses.

RESULTS

Countries may wish to avoid the financial costs of vaccination and risks for vaccine-associated paralytic polio following eradication of wild polioviruses, which may lead them to reduce their use of OPV. However, reducing or stopping vaccination too soon and without coordination poses serious risks, including the possibility of reimportation of wild polioviruses and the possibility of vaccine-derived polioviruses. Analysis of the risks for potential outbreaks suggests the need for creation and maintenance of a global stockpile of vaccine for outbreak response. Game theoretical considerations show that coordination of OPV cessation optimizes expected costs and risks globally, despite the potential perceived incentives for countries to stop OPV earlier or later than other countries, or to continue OPV use indefinitely.

CONCLUSIONS

This article makes the strong case for global cooperation on risk management and suggests that even though individual countries may perceive their own risks as small, risks at the global level warrant cooperative action and coordination of OPV cessation.

摘要

背景

成功根除一种疾病需要全球合作以实现共同目标。终局协调看似是成功的一项明显要求,但这并不能确保合作会发生。

目的

分析探讨维持全球脊髓灰质炎根除工作所需的合作,具体涉及创建全球脊髓灰质炎疫苗储备以及协调口服脊髓灰质炎病毒疫苗(OPV)停用事宜。

设计

运用风险与决策分析以及博弈论概念,我们模拟了在全球成功阻断野生脊髓灰质炎病毒传播后的20年时间范围内,全球合作在管理与脊髓灰质炎病毒相关风险方面的重要性。

结果

在野生脊髓灰质炎病毒被根除后,各国可能希望避免疫苗接种的财务成本以及疫苗相关麻痹型脊髓灰质炎的风险,这可能导致它们减少OPV的使用。然而,过早且无协调地减少或停止疫苗接种会带来严重风险,包括野生脊髓灰质炎病毒重新输入的可能性以及疫苗衍生脊髓灰质炎病毒的可能性。对潜在疫情风险的分析表明,需要创建和维持用于应对疫情的全球疫苗储备。博弈论考量显示,OPV停用的协调可在全球范围内优化预期成本和风险,尽管各国可能认为存在早于或晚于其他国家停止OPV使用,或无限期继续使用OPV的潜在诱因。

结论

本文有力地论证了在风险管理方面开展全球合作的必要性,并表明尽管个别国家可能认为自身风险较小,但全球层面的风险需要采取合作行动以及协调OPV停用。

相似文献

1
The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.在管理和维持消灭脊髓灰质炎工作中开展合作的理由:储备需求与口服脊髓灰质炎疫苗的协调停用
Medscape J Med. 2008;10(8):190. Epub 2008 Aug 13.
2
Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.脊髓灰质炎终结阶段疫情应对策略及潜在疫苗储备需求的特征分析
BMC Infect Dis. 2016 Mar 24;16:137. doi: 10.1186/s12879-016-1465-7.
3
Risk management in a polio-free world.无脊髓灰质炎世界中的风险管理。
Risk Anal. 2006 Dec;26(6):1441-8. doi: 10.1111/j.1539-6924.2006.00840.x.
4
A vision of a world without polio: the OPV cessation strategy.一个无脊髓灰质炎世界的愿景:口服脊髓灰质炎疫苗停用策略。
Biologicals. 2006 Jun;34(2):75-9. doi: 10.1016/j.biologicals.2006.03.005. Epub 2006 May 8.
5
Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.全球协调停止使用血清型 3 口服脊髓灰质炎疫苗(OPV)之前的预期影响,血清型 1 OPV。
Risk Anal. 2021 Feb;41(2):312-319. doi: 10.1111/risa.13590. Epub 2020 Sep 16.
6
Strengths and weaknesses of current polio vaccines--a view from industry.当前脊髓灰质炎疫苗的优缺点——来自行业的观点
Dev Biol (Basel). 2001;105:61-6.
7
Modeling the dynamics of oral poliovirus vaccine cessation.建模口服脊髓灰质炎疫苗停用的动力学。
J Infect Dis. 2014 Nov 1;210 Suppl 1:S475-84. doi: 10.1093/infdis/jit845.
8
Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.消灭脊灰:全世界的儿科医生如何助力永远终结这种致残疾病
Pediatrics. 2015 Jan;135(1):196-202. doi: 10.1542/peds.2014-3163.
9
Possible global strategies for stopping polio vaccination and how they could be harmonized.停止脊髓灰质炎疫苗接种的可能全球策略以及如何使其协调一致。
Dev Biol (Basel). 2001;105:153-8; discussion 159.
10
Cost analysis of post-polio certification immunization policies.小儿麻痹症认证免疫政策的成本分析
Bull World Health Organ. 2004 Jan;82(1):9-15. Epub 2004 Feb 26.

引用本文的文献

1
Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV).在全球协调停止使用二价口服脊髓灰质炎疫苗(bOPV)之前提高人群免疫力。
Pathogens. 2024 Sep 17;13(9):804. doi: 10.3390/pathogens13090804.
2
Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.支持全球消灭脊髓灰质炎的脊髓灰质炎病毒传播综述与经济建模:2020 - 2024年
Pathogens. 2024 May 22;13(6):435. doi: 10.3390/pathogens13060435.
3
Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.协调全球停用口服脊髓灰质炎疫苗:方案和潜在后果。
Risk Anal. 2024 Feb;44(2):366-378. doi: 10.1111/risa.14158. Epub 2023 Jun 21.
4
Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccination.评估bOPV加强免疫和IPV再接种的免疫效果。
NPJ Vaccines. 2023 Mar 18;8(1):44. doi: 10.1038/s41541-023-00642-w.
5
Outbreak response strategies with type 2-containing oral poliovirus vaccines.含 2 型成分的口服脊髓灰质炎疫苗的暴发应对策略。
Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A142-A152. doi: 10.1016/j.vaccine.2022.10.060. Epub 2022 Nov 17.
6
Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.消灭脊髓灰质炎终局疫苗选择的卫生经济学分析:2022-2036 年。
Expert Rev Vaccines. 2022 Nov;21(11):1667-1674. doi: 10.1080/14760584.2022.2128108. Epub 2022 Oct 5.
7
Using integrated modeling to support the global eradication of vaccine-preventable diseases.运用综合建模支持全球消除疫苗可预防疾病。
Syst Dyn Rev. 2018 Jun;34(1-2):78-120. doi: 10.1002/sdr.1589.
8
Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.血清型 2 口服脊髓灰质炎疫苗(OPV2)的选择和延迟应对疫情的后果。
Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A136-A141. doi: 10.1016/j.vaccine.2021.04.061. Epub 2021 May 14.
9
A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.美国口服脊髓灰质炎疫苗预防 COVID-19 的健康经济分析。
Risk Anal. 2021 Feb;41(2):376-386. doi: 10.1111/risa.13614. Epub 2020 Oct 20.
10
Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.回顾 2000 年至 2019 年期间为支持全球根除脊髓灰质炎而进行的脊髓灰质炎病毒建模。
Expert Rev Vaccines. 2020 Jul;19(7):661-686. doi: 10.1080/14760584.2020.1791093. Epub 2020 Aug 1.

本文引用的文献

1
Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management.根除后脊髓灰质炎风险管理决策分析模型的不确定性和敏感性分析
Risk Anal. 2008 Aug;28(4):855-76. doi: 10.1111/j.1539-6924.2008.01078.x. Epub 2008 Jul 4.
2
The risks, costs, and benefits of possible future global policies for managing polioviruses.未来全球管理脊髓灰质炎病毒可能采取的政策所带来的风险、成本和益处。
Am J Public Health. 2008 Jul;98(7):1322-30. doi: 10.2105/AJPH.2007.122192. Epub 2008 May 29.
3
Rinderpest. Driven to extinction.牛瘟。已被消灭。
Science. 2008 Mar 21;319(5870):1606-9. doi: 10.1126/science.319.5870.1606.
4
Laboratory surveillance for wild and vaccine-derived polioviruses--worldwide, January 2006-June 2007.2006年1月至2007年6月全球野生和疫苗衍生脊髓灰质炎病毒的实验室监测
MMWR Morb Mortal Wkly Rep. 2007 Sep 21;56(37):965-9.
5
Eradication versus control for poliomyelitis: an economic analysis.脊髓灰质炎的根除与控制:一项经济分析。
Lancet. 2007 Apr 21;369(9570):1363-1371. doi: 10.1016/S0140-6736(07)60532-7.
6
Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.古巴灭活脊髓灰质炎疫苗随机安慰剂对照试验
N Engl J Med. 2007 Apr 12;356(15):1536-44. doi: 10.1056/NEJMoa054960.
7
Evaluation of response scenarios to potential polio outbreaks using mathematical models.使用数学模型评估对潜在脊髓灰质炎疫情的应对方案。
Risk Anal. 2006 Dec;26(6):1541-56. doi: 10.1111/j.1539-6924.2006.00843.x.
8
The costs of future polio risk management policies.未来脊髓灰质炎风险管理政策的成本。
Risk Anal. 2006 Dec;26(6):1507-31. doi: 10.1111/j.1539-6924.2006.00842.x.
9
Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.根除后野生或疫苗衍生脊髓灰质炎病毒导致麻痹性疾病的风险。
Risk Anal. 2006 Dec;26(6):1471-505. doi: 10.1111/j.1539-6924.2006.00827.x.
10
Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management.根除脊髓灰质炎病毒及停止使用口服脊髓灰质炎疫苗后的病毒控制:识别风险以改进管理
Risk Anal. 2006 Dec;26(6):1449-69. doi: 10.1111/j.1539-6924.2006.00844.x.